雷替曲塞用于结直肠癌术中腹腔灌注化疗的近期安全性评估

Short-term safety evaluation of intraperitoneal chemotherapy with Raltitrexed for colorectal cancer

目的评估雷替曲塞用于结直肠癌患者术中腹腔灌注化疗的近期安全性以及可行性。方法回顾性分析2017年7月至2018年10月期间就诊于中国医学科学院肿瘤医院结直肠外科并进行手术治疗患者的临床资料,分为研究组和对照组,研究组40例,对照组40例,研究组在关腹后经引流管行雷替曲塞腹腔灌注化疗,对照组用蒸馏水冲洗后关腹。分析两组患者术后并发症发生率、血液学毒性、肝肾功能、胃肠道功能恢复等近期安全性的差异。结果两组患者术后并发症发生率、血液学毒性、肝肾功能、胃肠道功能恢复时间相比较差异均无统计学意义(均P>0.05)。结论雷替曲塞用于结直肠癌患者术中灌注化疗具有良好的安全性及耐受性,不增加术后并发症。

Objective To evaluate of the recent safety and feasibility of intraoperative intraperitoneal chemotherapy with Raltitrexed for colorectal cancer patients. Methods The clinical data of colorectal cancer patients undergoing surgery from the National Cancer Center from July 2017 to October 2018 were retrospectively analyzed. 80 colorectal cancer patients who underwent radical surgery were divided into two groups. The Raltitrexed group (40 patients), who received intraoperative intraperitoneal perfusion chemotherapy with Raltitrexed and the control group (40 patients), who did not receive intraoperative intraperitoneal perfusion chemotherapy. Analysis of the recent safety differences between the two groups in terms of postoperative complications, liver and kidney function, hematological toxicity, and time of gastrointestinal function recovery. Results There was no significant differences in the incidence of postoperative complications, liver and kidney function, blood toxicity and recovery time of gastrointestinal function between the two groups (all P>0.05). Conclusions Intraoperative perfusion with Raltitrexed for patients with colorectal cancer has good safety and tolerability, and does not increase postoperative complications.